Climb Bio reported second quarter 2026 financial results on August 6, 2026, showing a net loss of $13.5 million compared to $8.7 million in the prior year period. Cash and marketable securities totaled $239.2 million as of June 30, 2026, following an April private placement that generated approximately $110 million in gross proceeds, extending the cash runway into the second half of 2028. The company provided clinical updates for its lead programs: CLYM116 Phase 1 data will be presented at an R&D Spotlight on September 3, 2026, with dosing anticipated to begin in a Phase 2 IgA nephropathy trial in Q3 2026. Budoprutug trials continue across primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, with data expected in Q4 2026. Climb Bio operates as a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases.
